163 related articles for article (PubMed ID: 22614243)
1. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.
Simioni C; Neri LM; Tabellini G; Ricci F; Bressanin D; Chiarini F; Evangelisti C; Cani A; Tazzari PL; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Capitani S; Martelli AM
Leukemia; 2012 Nov; 26(11):2336-42. PubMed ID: 22614243
[TBL] [Abstract][Full Text] [Related]
2. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
[TBL] [Abstract][Full Text] [Related]
3. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.
Evangelisti C; Ricci F; Tazzari P; Tabellini G; Battistelli M; Falcieri E; Chiarini F; Bortul R; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
Leukemia; 2011 May; 25(5):781-91. PubMed ID: 21331075
[TBL] [Abstract][Full Text] [Related]
4. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
[TBL] [Abstract][Full Text] [Related]
5. Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia.
Evangelisti C; Ricci F; Tazzari P; Chiarini F; Battistelli M; Falcieri E; Ognibene A; Pagliaro P; Cocco L; McCubrey JA; Martelli AM
J Cell Physiol; 2011 Mar; 226(3):822-31. PubMed ID: 20857426
[TBL] [Abstract][Full Text] [Related]
6. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.
Zhao YY; Tian Y; Zhang J; Xu F; Yang YP; Huang Y; Zhao HY; Zhang JW; Xue C; Lam MH; Yan L; Hu ZH; Dinglin XX; Zhang L
Drug Des Devel Ther; 2014; 8():1827-37. PubMed ID: 25336925
[TBL] [Abstract][Full Text] [Related]
7. The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy.
Simioni C; Martelli AM; Cani A; Cetin-Atalay R; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2013 Sep; 4(9):1496-506. PubMed ID: 24036604
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia cells by inhibiting Akt/mTOR and activating p38-MAPK.
Ge J; Liu Y; Li Q; Guo X; Gu L; Ma ZG; Zhu YP
Biomed Environ Sci; 2013 Nov; 26(11):902-11. PubMed ID: 24331535
[TBL] [Abstract][Full Text] [Related]
9. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
Alameen AA; Simioni C; Martelli AM; Zauli G; Ultimo S; McCubrey JA; Gonelli A; Marisi G; Ulivi P; Capitani S; Neri LM
Oncotarget; 2016 Aug; 7(34):55690-55703. PubMed ID: 27494886
[TBL] [Abstract][Full Text] [Related]
10. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.
Neri LM; Cani A; Martelli AM; Simioni C; Junghanss C; Tabellini G; Ricci F; Tazzari PL; Pagliaro P; McCubrey JA; Capitani S
Leukemia; 2014 Apr; 28(4):739-48. PubMed ID: 23892718
[TBL] [Abstract][Full Text] [Related]
11. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
Pereira JK; Machado-Neto JA; Lopes MR; Morini BC; Traina F; Costa FF; Saad ST; Favaro P
Eur J Cancer; 2015 Sep; 51(14):2076-85. PubMed ID: 26238016
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
[TBL] [Abstract][Full Text] [Related]
13. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.
Simioni C; Cani A; Martelli AM; Zauli G; Tabellini G; McCubrey J; Capitani S; Neri LM
Oncotarget; 2014 Oct; 5(20):10034-47. PubMed ID: 25296981
[TBL] [Abstract][Full Text] [Related]
14. Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy.
Fujiwara K; Iwado E; Mills GB; Sawaya R; Kondo S; Kondo Y
Int J Oncol; 2007 Oct; 31(4):753-60. PubMed ID: 17786305
[TBL] [Abstract][Full Text] [Related]
15. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.
Martelli AM; Lonetti A; Buontempo F; Ricci F; Tazzari PL; Evangelisti C; Bressanin D; Cappellini A; Orsini E; Chiarini F
Adv Biol Regul; 2014 Sep; 56():6-21. PubMed ID: 24819383
[TBL] [Abstract][Full Text] [Related]
16. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications.
Grimaldi C; Chiarini F; Tabellini G; Ricci F; Tazzari PL; Battistelli M; Falcieri E; Bortul R; Melchionda F; Iacobucci I; Pagliaro P; Martinelli G; Pession A; Barata JT; McCubrey JA; Martelli AM
Leukemia; 2012 Jan; 26(1):91-100. PubMed ID: 21968881
[TBL] [Abstract][Full Text] [Related]
17. Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell lines.
Guo D; Ye J; Dai J; Li L; Chen F; Ma D; Ji C
Leuk Res; 2009 May; 33(5):678-85. PubMed ID: 19091404
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
Bressanin D; Evangelisti C; Ricci F; Tabellini G; Chiarini F; Tazzari PL; Melchionda F; Buontempo F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
Oncotarget; 2012 Aug; 3(8):811-23. PubMed ID: 22885370
[TBL] [Abstract][Full Text] [Related]
19. Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes.
Tan S; Ng Y; James DE
Biochem J; 2011 Apr; 435(2):539-44. PubMed ID: 21348862
[TBL] [Abstract][Full Text] [Related]
20. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism.
Chiarini F; Del Sole M; Mongiorgi S; Gaboardi GC; Cappellini A; Mantovani I; Follo MY; McCubrey JA; Martelli AM
Leukemia; 2008 Jun; 22(6):1106-16. PubMed ID: 18385752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]